Skip to main content
. 2017 Dec 20;10(2):315–324. doi: 10.1080/19420862.2017.1409319

Figure 4.

Figure 4.

IAB exhibits superior ADCC activity in vitro and minimal blood toxicity in vivo. (A) Relative ADCC activity of IAB, CV1 Fc and atezolizumab in ADCC reporter assay. (n = 3); Analysis of red blood cell (B), hematocrit (C) and hemoglobin (D) in mice intraperitoneal injected with 100 mg/Kg of IAB or parental proteins (n = 5). Data are reported as the means ± SD, *: p<0.05, **: p <0.01, ***: p <0.001; NS: non-significant (unpaired Student's t test).